Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The ONWARDS insulin icodec trials

A round-up of the ONWARDS phase 3 clinical trials evaluating the novel weekly insulin icodec in people with diabetes.
ADVANCED SEARCH
Log in
Top
Cancer Immunology, Immunotherapy
Published in: Cancer Immunology, Immunotherapy 9/2012

01-09-2012 | Original article

Evaluation of CTLA-4 expression and relevance as a novel prognostic factor in patients with non-small cell lung cancer

Authors: Sandra Salvi, Vincenzo Fontana, Simona Boccardo, Domenico Franco Merlo, Edoardo Margallo, Stefania Laurent, Anna Morabito, Erika Rijavec, Maria Giovanna Dal Bello, Marco Mora, Giovanni Battista Ratto, Francesco Grossi, Mauro Truini, Maria Pia Pistillo

Published in: Cancer Immunology, Immunotherapy | Issue 9/2012

Login to get access

Abstract

The role of CTLA-4 in negative regulation of T-cell mediated immune response is particularly well established. Much less is known about its expression and function in tumour cells, and to our knowledge, no data are available on its possible impact on prognosis of NSCLC patients. We investigated CTLA-4 expression and prognostic role in 81 patients with radically resected stage I–III NSCLC. The analysis was performed by tissue microarray immunohistochemistry, and the median H-score of 20 was used as a threshold to define CTLA-4 overexpressing tumours. Correlation with standard prognostic factors was performed by using absolute and relative fold change indexes. Hazard ratios (HR) and corresponding 95% confidence limits (95% CL) were computed through the Cox model. A higher frequency of CTLA-4 overexpression (>20) was found in non-squamous than in squamous NSCLC (52.8 vs. 35.7%) and in Ki67 ≤ 15 expressing tumours, as compared to those with Ki67 > 15 (51.5 vs. 38.7%). A reduced death rate was found in CTLA-4 overexpressing tumours (HR = 0.60, 95% CL = 0.28/1.23), and a further decrease was observed when considering tumours with CTLA-4 > 20 and Ki67 ≤ 15, in comparison with tumours with CTLA-4 ≤ 20 and Ki67 > 15 (HR = 0.41; 95% CL = 0.15/1.13). Our observational and exploratory study provides a first and promising indication for an independent prognostic effect of CTLA-4 overexpression in radically resected NSCLC. We presume that this effect relies on modulation of the interaction of microscopic disease with CTLA-4-ligands expressing cells leading to NSCLC cell death.
Literature
1.
Krummel MF, Allison JP (1996) CTLA-4 engagement inhibits IL-2 accumulation and cell cycle progression upon activation of resting T cells. J Exp Med 183:2533–2540PubMedCrossRef
2.
Brunner MC, Chambers CA, Chan FK, Hanke J, Winoto A, Allison JP (1999) CTLA-4-Mediated inhibition of early events of T cell proliferation. J Immunol 162:5813–5820PubMed
3.
Teft WA, Kirchhof MG, Madrenas J (2006) A molecular perspective of CTLA-4 function. Annu Rev Immunol 24:65–97PubMedCrossRef
4.
Carreno BM, Bennett F, Chau TA, Ling V, Luxenberg D, Jussif J et al (2000) CTLA-4 (CD152) can inhibit T cell activation by two different mechanisms depending on its level of cell surface expression. J Immunol 165:1352–1356PubMed
5.
Jain N, Nguyen H, Chambers C, Kang J (2010) Dual function of CTLA-4 in regulatory T cells and conventional T cells to prevent multiorgan autoimmunity. Proc Natl Acad Sci USA 107:1524–1528PubMedCrossRef
6.
Merlo A, Tenca C, Fais F, Battini L, Ciccone E, Grossi CE, Saverino D (2005) Inhibitory receptors CD85j, LAIR-1, and CD152 down-regulate immunoglobulin and cytokine production by human B lymphocytes. Clin Diagn Lab Immunol 12:705–712PubMed
7.
Wang XB, Giscombe R, Yan Z, Heiden T, Xu D, Lefvert AK (2002) Expression of CTLA-4 by human monocytes. Scand J Immunol 55:53–60PubMedCrossRef
8.
Laurent S, Carrega P, Saverino D, Piccioli P, Camoriano M, Morabito A et al (2010) CTLA-4 is expressed by human monocyte-derived dendritic cells and regulates their functions. Hum Immunol 71:934–941PubMedCrossRef
9.
Kaufman KA, Bowen JA, Tsai AF, Bluestone JA, Hunt JS, Ober C (1999) The CTLA-4 gene is expressed in placental fibroblasts. Mol Hum Reprod 5:84–87PubMedCrossRef
10.
Nagaraju K, Raben N, Villalba ML, Danning C, Loeffler LA, Lee E et al (1999) Costimulatory markers in muscle of patients with idiopathic inflammatory myopathies and in cultured muscle cells. Clin Immunol 92:161–169PubMedCrossRef
11.
Pistillo MP, Tazzari PL, Palmisano GL, Pierri I, Bolognesi A, Ferlito F et al (2003) CTLA-4 is not restricted to the lymphoid cell lineage and can function as a target molecule for apoptosis induction of leukemic cells. Blood 101:202–209PubMedCrossRef
12.
Joshi AD, Hegde GV, Dickinson JD, Mittal AK, Lynch JC, Eudy JD et al (2007) ATM, CTLA4, MNDA, and HEM1 in high versus low CD38 expressing B-cell chronic lymphocytic leukemia. Clin Cancer Res 13:5295–5304PubMedCrossRef
13.
Kosmaczewska A, Ciszak L, Suwalska K, Wolowiec D, Frydecka I (2005) CTLA-4 overexpression in CD19+/CD5+ cells correlates with the level of cell cycle regulators and disease progression in B-CLL patients. Leukemia 19:301–314PubMedCrossRef
14.
Mao H, Zhang L, Yang Y, Zuo W, Bi Y, Gao W et al (2010) New insights of CTLA-4 into its biological function in breast cancer. Curr Cancer Drug Targets 10:728–736PubMedCrossRef
15.
Contardi E, Palmisano GL, Tazzari PL, Martelli AM, Falà F, Fabbi M et al (2005) CTLA-4 is constitutively expressed on tumour cells and can trigger apoptosis upon ligand interaction. Int J Cancer 117:538–550PubMedCrossRef
16.
Shah KV, Chien AJ, Yee C, Moon RT (2008) CTLA-4 is a direct target of Wnt/beta-catenin signaling and is expressed in human melanoma tumours. J Invest Dermatol 128:2870–2879PubMedCrossRef
17.
Hodi FS, O’Day SJ, McDermott DF, Weber RW, Sosman JA, Haanen JB et al (2010) Improved survival with ipilimumab in patients with metastatic melanoma. N Engl J Med 19(363):711–723CrossRef
18.
Tarhini A, Lo E, Minor DR (2010) Releasing the brake on the immune system: ipilimumab in melanoma and other tumours. Cancer Biother Radiopharm 25:601–613PubMedCrossRef
19.
Leach DR, Krummel MF, Allison JP (1996) Enhancement of antitumour immunity by CTLA-4 blockade. Science 27:1734–1736CrossRef
20.
Maker AV, Phan GQ, Attia P, Yang JC, Sherry RM, Topalian SL et al (2005) Tumour regression and autoimmunity in patients treated with cytotoxic T lymphocyte-associated antigen 4 blockade and interleukin 2: a phase I/II study. Ann Surg Oncol 12:1005–1016PubMedCrossRef
21.
Page DB, Yuan J, Wolchok JD (2010) Targeting cytotoxic T-lymphocyte antigen 4 in immunotherapies for melanoma and other cancers. Immunotherapy 2(3):367–379PubMedCrossRef
22.
Zheng H, Li Y, Wang X, Zhang X, Wang X (2010) Expression and significance of gp96 and immune-related gene CTLA-4, CD8 in lung cancer tissues. Zhongguo Fei Ai Za Zhi 13:790–794PubMed
23.
Naruke T, Suemasu K, Ishikawa S (1978) Lymph node mapping and curability at various levels of metastasis in resected lung cancer. J Thorac Cardiovasc Surg 76:832–839PubMed
24.
Sobin LH, Wittekind CH (eds) (1997) TNM classification of malignant tumours, 5th edn. Wiley-Liss, New York, pp 59–62
25.
Sobin LH and Pathologists from 14 Countries World Health Organization International Histological Classification of Tumours (1999) Histological typing of lung and pleural tumours, 3rd edn. Springer, Geneva
26.
Tokuhara T, Hattori N, Ishida H, Hirai T, Higashiyama M, Kodama K, Miyake M (2006) Clinical significance of aminopeptidase N in non-small cell lung cancer. Clin Cancer Res 1(12):3971–3978CrossRef
27.
Dertsiz L, Ozbilim G, Kayisli Y, Gokhan GA, Demircan A, Kayisli UA (2005) Differential expression of VASP in normal lung tissue and lung adenocarcinomas. Thorax 60:576–581PubMedCrossRef
28.
Hosmer D, Lemeshow S (1999) Applied survival analysis: regression modeling of time to event data. Wiley, New York
29.
30.
Bienz M (2005) Beta-catenin: a pivot between cell adhesion and Wnt signalling. Curr Biol 15:R64–R67PubMedCrossRef
31.
Gavert N, Ben-Ze’ev A (2007) Beta-catenin signaling in biological control and cancer. J Cell Biochem 102:820–828PubMedCrossRef
32.
Liu D, Huang C, Kameyama K, Hayashi E, Yamauchi A, Kobayashi S, Yokomise H (2001) E-cadherin expression associated with differentiation and prognosis in patients with non-small cell lung cancer. Ann Thorac Surg 71:949–955PubMedCrossRef
33.
Kase S, Sugio K, Yamazaki K, Okamoto T, Yano T, Sugimachi K (2000) Expression of E-cadherin and beta-catenin in human non-small cell lung cancer and the clinical significance. Clin Cancer Res 6:4789–4796PubMed
34.
Gerdes J, Lemke H, Baisch H, Wacker HH, Schwab U, Stein H (1984) Cell cycle analysis of a cell proliferation-associated human nuclear antigen defined by the monoclonal antibody Ki-67. J Immunol 133:1710–1715PubMed
35.
Martin B, Paesmans M, Mascaux C, Berghmans T, Lothaire P, Meert AP et al (2004) Ki-67 expression and patients survival in lung cancer: systematic review of the literature with meta-analysis. Br J Cancer 91:2018–2025PubMedCrossRef
36.
Zou W, Chen L (2005) Inhibitory B7-family molecules in the tumour microenvironment. Nat Rev Immunol 8:467–477CrossRef
37.
Metadata
Title
Evaluation of CTLA-4 expression and relevance as a novel prognostic factor in patients with non-small cell lung cancer
Authors
Sandra Salvi
Vincenzo Fontana
Simona Boccardo
Domenico Franco Merlo
Edoardo Margallo
Stefania Laurent
Anna Morabito
Erika Rijavec
Maria Giovanna Dal Bello
Marco Mora
Giovanni Battista Ratto
Francesco Grossi
Mauro Truini
Maria Pia Pistillo
Publication date
01-09-2012
Publisher
Springer-Verlag
Published in
Cancer Immunology, Immunotherapy / Issue 9/2012
Print ISSN: 0340-7004
Electronic ISSN: 1432-0851
DOI
https://doi.org/10.1007/s00262-012-1211-y

Other articles of this Issue 9/2012

Cancer Immunology, Immunotherapy 9/2012 Go to the issue

Symposium-in-writing paper

How to connect an IgE-driven response with CTL activity?

Editorial

The nascent field of AllergoOncology

Symposium-in-writing paper

Recombinant IgE antibodies for passive immunotherapy of solid tumours: from concept towards clinical application

Symposium-in-writing paper

Recombinant IgE antibody engineering to target EGFR

Symposium-in-writing paper

IgE and chemotherapy

Symposium-in-writing paper

The roles of mast cells in anticancer immunity
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits